2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

5431 Efficacy and safety of a chemotherapy-free polatuzumab vedotin, acalabrutinib, rituximab, and lenalidomide regimen as frontline therapy for unfit or frail patients with diffuse large B-cell lymphoma

Qian Wang, MS, Tao You, MD2, Jin Zhou, MD3, Yun Wang4, Xiangping Zong5, Depei Wu Sr, MD6, Haiwen Huang, PhD7
1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
2 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
3 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
4 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
5 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
6 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
7 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Background: Older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are unfit or frail often have limited tolerance of standard immunochemotherapy. Effective, low-toxicity, chemotherapy-free frontline strategies remain an unmet clinical need.

Aims: To evaluate the efficacy and safety of frontline polatuzumab vedotin, acalabrutinib, rituximab, and lenalidomide (Pola-AR2), and to benchmark response outcomes against the POLARIX older subgroup using an International Prognostic Index (IPI)-adjusted matching-adjusted indirect comparison (MAIC).

Methods: This retrospective real-world study included 21 patients with newly diagnosed DLBCL considered unsuitable for standard chemotherapy. Pola-AR2 comprised polatuzumab vedotin 1.8 mg/kg intravenously on day 1, rituximab 375 mg/m² intravenously on day 2, acalabrutinib 100 mg orally twice daily on days 1–21, and lenalidomide 25 mg orally once daily on days 1–10, every 21 days for up to six cycles, followed by acalabrutinib maintenance for 1 year. PET/CT response, progression-free survival (PFS), overall survival (OS), and treatment-related adverse events were assessed. An exploratory unanchored MAIC weighted individual patient data to the published IPI distribution of the POLARIX subgroup aged ≥60 years.

Results: Median age was 77 years (range, 68–88); 42.9% were aged ≥80 years, 81.0% had Ann Arbor stage III–IV disease, 71.4% had IPI 3–5, 71.4% had non-GCB disease, and 90.5% had extranodal involvement. The objective response rate (ORR) was 90.5% (19/21), including complete response (CR) in 17 patients (81.0%) and partial response in 2 (9.5%); 2 patients (9.5%) had progressive disease. At a median follow-up of 16.0 months (range, 5.0–32.0), median PFS and OS were not reached. Three PFS events occurred, including two deaths; 18 patients remained progression-free and 19 were alive at data cutoff. Grade 3–4 neutropenia and thrombocytopenia occurred in 32% and 10.5%, respectively. Two patients developed rash, which resolved with corticosteroids and intravenous immunoglobulin. No atrial fibrillation, major bleeding, or clinically significant organ toxicity was observed. The primary MAIC included 12 patients (effective sample size, 11.99). Weighted ORR/CRR were 91.5%/83.0% for Pola-AR2, 86.2%/80.7% for Pola-R-CHP, and 84.9%/76.1% for R-CHOP. All 95% confidence intervals for rate differences crossed zero.

Summary/Conclusion: Frontline Pola-AR2 demonstrated encouraging activity and manageable toxicity in unfit or frail patients with DLBCL. The exploratory MAIC suggested response outcomes not inconsistent with POLARIX benchmarks, but did not establish superiority, equivalence, or noninferiority. Larger multicenter studies using standardized frailty assessment and harmonized prognostic variables are warranted.

Haiwen Huang, PhD: No relevant conflicts of interest to declare.